PMS-ROSIGLITAZONE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

ROSIGLITAZONE (ROSIGLITAZONE MALEATE)

Disponible desde:

PHARMASCIENCE INC

Código ATC:

A10BG02

Designación común internacional (DCI):

ROSIGLITAZONE

Dosis:

2MG

formulario farmacéutico:

TABLET

Composición:

ROSIGLITAZONE (ROSIGLITAZONE MALEATE) 2MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

THIAZOLIDINEDIONES

Resumen del producto:

Active ingredient group (AIG) number: 0138802002; AHFS:

Estado de Autorización:

CANCELLED PRE MARKET

Fecha de autorización:

2017-08-03

Ficha técnica

PRODUCT MONOGRAPH
PR
PMS-ROSIGLITAZONE
Rosiglitazone (as Rosiglitazone Maleate)
2 mg, 4 mg and 8 mg Tablets
Professed Standard
Antidiabetic Agent
Insulin Resistance Reducing Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
June 20, 2016
_ _
Submission Control No: 195686_ _
_ _
_ _
_pms-ROSIGLITAZONE Product Monograph _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................................
10
DRUG INTERACTIONS
........................................................................................................................................
15
DOSAGE AND ADMINISTRATION
....................................................................................................................
18
OVERDOSAGE
......................................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................
19
STORAGE AND STABILITY
.................................................................................................................